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Efficacy and Safety Findings of the Global Phase IV Tarceva Lung
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Introduction: Erlotinib is a small molecule inhibitor of epidermal
growth factor receptor tyrosine-kinase activity that has been shown
to significantly increase survival for patients with previously treated
advanced non-small cell lung cancer. Here, we report safety and
efficacy data from a large, global, open-label, phase IV trial of
erlotinib (Tarceva Lung Cancer Survival Treatment).
Methods: Patients who had previously failed on chemotherapy or
radiotherapy and were unsuitable for these treatments were treated with
oral erlotinib (150 mg/d) until disease progression or unacceptable toxicity.
Results: The disease control rate was 69% in 5394 patients for
whom best response data were available. Survival data were avail-
able for 6580 patients. Median progression-free and overall survival
times were 3.25 months and 7.9 months, respectively. The 1-year
survival rate was 37.7%. Among the 6580 patients included in the
safety analysis, 799 (12%) experienced one or more erlotinib-related
adverse events (AEs, other than prespecified AEs defined in the
protocol), and only 4% experienced an erlotinib-related serious AE.
Of the 6580 patients for whom data were available, dose reductions
were reported in 1096 (17%), the majority (95%) due to an erlotinib-
related AE (most commonly rash 65% or diarrhea 10%). Treatment
was discontinued for 337 patients (5%) because of erlotinib-related
AEs. Incidence of erlotinib-related rash was investigated as a sep-
arate end point. Seventy-one percent of patients for whom data were
available experienced erlotinib-related rash; of these, the majority of
cases were grade 1/2 (59%).
Conclusions: These data confirm the favorable efficacy and safety
profile of erlotinib in a large heterogeneous non-small cell lung
cancer population.
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Erlotinib is a highly potent, orally active, reversible inhib-itor of epidermal growth factor receptor (EGFR) tyrosine-
kinase (TK) activity. The importance of EGFR in tumor
growth and progression has been demonstrated in clinical
trials where EGFR inhibition has led to improved efficacy
outcomes in patients with non-small cell lung cancer
(NSCLC). Erlotinib prolonged overall survival (OS) versus
placebo in patients with advanced NSCLC who had received
at least one line of chemotherapy (BR.21). Erlotinib was also
shown to significantly prolong progression-free survival
(PFS), delay symptom deterioration, and provide quality-of-
life benefits.1,2 In the BR.21 trial, the 1-year survival rate was
31.2% with erlotinib and 21.5% with placebo, representing a
45% improvement with erlotinib. Notably, survival benefit
was observed across a broad range of patient subgroups.
Erlotinib was well tolerated, with rash and diarrhea being the
most common toxicities (generally mild or moderate).
Certain groups of patients with NSCLC, such as those
with adenocarcinoma histology, women, Asian ethnicity, and
non (minimal) smokers are reported to be more likely to have
tumor responses to EGFR TK inhibitors (TKIs) than other
groups.3–5 One possible explanation for this observation may
be that these groups are also more likely to have activating
mutations in the EGFR TK domain,6,7 which have been
shown to be associated with clinical responsiveness to the
EGFR TKIs erlotinib8 and gefitinib.9–11 In the BR.21 study,
patients with EGFR gene amplification had a higher response
rate than patients with a normal EGFR copy number.12
However, other studies show that the expression of EGFR in
tumor cells is not significantly associated with response to
EGFR TKIs.13,14 In the BR.21 study, gender and histology
were found to be strong prognostic factors, but neither was
predictive of a differential survival benefit with erlotinib
compared with placebo.1,15 Smoking history was the only
significant predictive factor. Furthermore, a subanalysis of
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the BR.21 study found that male smokers whose tumors
were predominantly of squamous cell histology had a
statistically significant survival benefit from erlotinib,
compared with placebo.16
Erlotinib is approved in more than 80 countries for the
treatment of NSCLC for patients who have received at least
one line of prior chemotherapy. The Tarceva Lung Cancer
Survival Treatment (TRUST) study was a large international,
open-label, phase IV study of erlotinib, designed to allow
access to erlotinib monotherapy for patients with advanced
stage IIIB/IV NSCLC who had previously failed on or were
considered unsuitable to receive standard chemotherapy or
radiotherapy and were ineligible for other erlotinib trials. In
each country, recruitment continued until erlotinib was
granted a license. A total of 513 centers across 51 countries
have participated in this trial. The study provided an oppor-
tunity to evaluate the efficacy and safety of erlotinib in a
broad patient population in a real-life clinical setting. The
impact of patient characteristics on clinical outcomes with
erlotinib was also assessed by examining specific patient
subgroups presumed to be predisposed to beneficial or detri-
mental outcomes during treatment with EGFR TKIs (albeit in
an uncontrolled setting). Here, we report final data from the
global population of the TRUST study.
MATERIALS AND METHODS
Inclusion and Exclusion Criteria
Patients aged 18 years or older with histologically or
cytologically confirmed, unresectable, stage IIIB/IV NSCLC
who had received at least one previous course of standard
chemotherapy or radiotherapy or were unsuitable for chemo-
therapy (and could not participate in another trial with erlo-
tinib) were eligible for TRUST. Additional criteria included
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) of 0 to 3; an estimated life expectancy of 12 weeks
or more; and adequate hematological, renal, and hepatic
function (serum bilirubin must have been1.5 upper limit of
normal). At least 3 weeks must have elapsed from the last
dose of previous therapy, and patients must have recovered
from any toxic effects of such therapies before enrolment.
Patients who had fully recovered from previous surgery
were eligible. Women of child-bearing potential were
required to test negative for pregnancy and agree to birth
control precaution.
Key exclusion criteria included any evidence of unsta-
ble systemic disease (including active infection, grade 4
hypertension, unstable angina, congestive heart failure, and
hepatic, renal, or metabolic disease); prior treatment with
anti-EGFR agents (including small molecules or monoclonal
antibodies); previous malignancies within the last 5 years
(other than cervical carcinoma or skin cancer that underwent
successful treatment); untreated brain metastases (newly di-
agnosed or preexisting) or spinal cord compression; and any
significant ophthalmologic abnormalities (including severe
dry eye syndrome, keratoconjunctivitis sicca, Sjo¨gren syn-
drome, severe exposure keratitis, or any other disorder likely
to increase the risk of corneal epithelial lesions).
The study complied with the Declaration of Helsinki
and Good Clinical Practice guidelines. Informed consent was
obtained from all patients, and the protocol was approved at
all participating centers by respective ethics committees.
Study Design and Treatment
This was a phase IV, open-label, single-arm study. Oral
erlotinib (F. Hoffman-La Roche, Switzerland) was adminis-
tered once daily at a dose of 150 mg to all patients until
disease progression, unacceptable toxicity, or death. Dose
interruption or reduction (in 50 mg/d decrements) was per-
mitted in the event of treatment-related adverse events (AEs).
The primary objective was to provide access to erlotinib
(before approval) for patients with stage IIIB/IV NSCLC who
had failed or were unsuitable for chemotherapy or radiother-
apy. Secondary objectives were to assess safety, best re-
sponse, PFS, and OS. The incidence and severity of erlotinib-
related rash was also a secondary end point for this study.
Clinical Assessments
Outcomes included best response as per investigator
assessment (complete response [CR], partial response [PR],
or stable disease [SD]), PFS, OS, and safety. Clinical and
laboratory assessments were conducted at baseline, then ev-
ery 4 weeks throughout the study. Tumor response was
assessed using RECIST,17 at least every 2 months (by
computerized tomography, magnetic resonance imaging,
or x-ray). For tumors classed as responding, a confirmatory
evaluation was carried out 4 weeks after the initial deter-
mination of response.
For safety and tolerability evaluations, AEs and
serious AEs (SAEs) of any cause were assessed and graded
using National Cancer Institute Common Toxicity Criteria
(NCI-CTC) version 3.0. Treatment-related AEs were re-
ported if they were not included on a list of prespecified AEs
defined in the study protocol (pruritus, dry skin, diarrhea,
nausea, vomiting, stomatitis, abdominal pain, fatigue, dys-
pnea, cough, anorexia, infection, conjunctivitis, and kerato-
conjunctivitis sicca). All treatment-related SAEs were re-
ported (regardless of whether the AE was included on the
prespecified list). The incidence and severity of erlotinib-
related rash were recorded as a secondary end point. The
incidence and severity of interstitial lung disease were re-
corded by exclusion diagnosis based on investigator assess-
ment according to NCI-CTC version 3.0 (pneumonitis and
pulmonary infiltrates were applicable). All erlotinib-related
AEs or SAEs resulting in treatment withdrawals were re-
corded (regardless of whether the AE was included on the
prespecified list). Erlotinib-related AEs or SAEs leading to
dose reduction or modification were also monitored (unless
they were included on the list of prespecified AEs). In the
event of an erlotinib-related AE that was not controlled by
best supportive care or not tolerated due to any reason
(regardless of severity), dose reductions were permitted (see
earlier). Within 2 weeks of a dose reduction, erlotinib-related
toxicity must have improved by 1 NCI-CTC grade and be
NCI-CTC grade 2 (or 1 for ocular toxicity), or a further
dose reduction was required. Dose reescalation was only
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permissible if the reason for reduction was erlotinib-related
rash and if the rash was grade 2.
Statistical Analysis
The overall response rate was defined as the sum of CR
and PR. A patient was assigned SD if they had a response
assessment of CR, PR, or SD at 1 visit but were not
confirmed as CR or PR (SD criteria must be met for 28
days). The disease control rate (DCR) was defined as the sum
of CR, PR, and SD. PFS was determined from the date of
erlotinib initiation until the date of first documented progres-
sion according to RECIST objective tumor assessment or
until the date of death for any reason in the absence of disease
progression. OS was determined from the date of start of
treatment until date of death (irrespective of cause).
Differences in OS and PFS according to clinical or disease
characteristics were analyzed using the log-rank test. Multivar-
iate analyses were performed for PFS and OS using the Cox
regression model and for DCR using the logistic regression
model. Baseline characteristics investigated for the analyses
comprised gender (male/female); age (65 years/65 years);
ethnicity (Asian/other); ECOG PS (PS 0 or 1/PS 2 or 3); stage
(stage IV/stage IIIB); histology (adenocarcinoma or bronchoal-
veolar carcinoma/squamous cell carcinoma); smoking status
(nonsmoker [smoked 100 cigarettes in their lifetime]/current
or former smoker [smoked100 cigarettes in their lifetime]).
Patients with a missing value for any of the baseline
characteristics were excluded from the multivariate anal-
ysis. For PFS, OS, and DCR analyses, factors were in-
cluded in the model using a stepwise approach: the criteria
for entry into the model being a p value 0.25 and the
criteria for remaining in the model being a p value 0.15.
RESULTS
Patients
Between November 2004 and June 2007, a total of
6665 patients were enrolled. The study database was locked
(cutoff date) on April 17, 2009. The study population (n 
6580) comprised all patients who had received at least one
dose of erlotinib. At the time of the data cutoff, 471 patients
had not experienced disease progression; 170 of these pa-
tients continued to receive erlotinib and 301 had discontinued
erlotinib treatment (mainly because of patient refusal [n 
86], symptomatic deterioration [n  84], lost to follow-up
[n  62], or study-related AE [n  35]). The safety popula-
tion (n  6580) comprised all patients who received at least
one dose of erlotinib at the cutoff date. The median duration
of follow-up was 2.56 months (range: 0–43.36 months) for
the 6548 patients with a known end date (the remaining 32
patients had no valid end date, mainly because of lost to
follow-up [n  22, 69%]).
Baseline patient and disease characteristics for the
study population are summarized in Table 1. Sixty percent of
the patients were men, and 77% were white. Seventy-six
percent of patients were PS 0 to 1, and the majority (69%)
were current/former smokers. Most patients had nonsqua-
mous tumor histology (76%), and 79% of patients had stage
IV disease. Thirty-seven percent of patients received erlotinib
as third-line therapy, 49% as second-line therapy, and 13% of
patients had no previous treatments and, therefore, received
erlotinib as first-line therapy.
Response and Survival
Best overall response data were available for 5394
patients, including 206 patients (4%) who were not evaluable
as response data were not collected at the first evaluation,
and their tumors were not evaluable for response at the
second evaluation (Table 2). The remaining 1186 patients
could not be included in the response analyses, because no
best response data were reported (mainly because of symp-
tomatic deterioration [36%] or death due to malignant
disease [22%]). The overall response rate with erlotinib
TABLE 1. Baseline Characteristics of Patients in the TRUST
Study (n  6580)
Characteristics
Median age, years (range) 63 (1991)
Gender, n (%)
Male 3974 (60)
Female 2606 (40)
Ethnic origin, n (%)
White 5057 (77)
Asian 1345 (20)
Black 29 (1)
Othera 149 (2)
ECOG PS, n (%)
0 1473 (22)
1 3504 (53)
2 1235 (19)
3 360 (5)
No data 8 (1)
Stage, n (%)
Stage IIIB 1376 (21)
Stage IV 5185 (79)
Other 15 (1)
No data 4 (1)
Histology, n (%)
Adenocarcinoma 3590 (55)
Bronchoalveolar carcinoma 372 (6)
Large-cell carcinoma 382 (6)
Squamous cell carcinoma 1552 (24)
Other 681 (10)
No data 3 (1)
Prior lines of chemotherapy, n (%)
None 869 (13)
One 3224 (49)
Two 2428 (37)
Other 59 (1)
Smoking history, n (%)
NS 2004 (30)
C/FS 4567 (69)
No data 9 (1)
a Includes patients with “Indian” ethnicity.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; NS, non-
smoker; C/FS, current or former smoker; TRUST, Tarceva Lung Cancer Survival
Treatment.
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was 13%, and the DCR was 69%. Survival data were
available for 6580 patients. Median PFS was 3.25 months
(n 6580; 95% confidence interval: [CI]: 3.06–3.42) (Figure
1A). Median OS was 7.9 months (n  6580; 95% CI:
7.59–8.28), with 18.8% of patients censored at the time of
data cutoff (Figure 1B). The 1-year survival rate was 37.7%
(95% CI: 36.5–38.9).
Response and Survival in Selected Subgroups
Response and survival data for erlotinib in subgroups,
defined on the basis of gender, histology, and smoking status,
are shown in Table 3. Tumor response rate varied consider-
ably between the different subgroups, from 4% in male
current/former smokers with squamous cell carcinoma to
28% in female nonsmokers with nonsquamous tumors. There
was also notable variability in the DCR, which ranged from
59% in male nonsmokers with squamous tumors to 79% in
female nonsmokers with nonsquamous tumors. The observed
median PFS ranged from at least 2.33 months (in male
nonsmokers with squamous tumors) to 7.19 months (in fe-
male nonsmokers, with nonsquamous tumors). Median PFS
for patients with erlotinib-related rash of grades 2 to 4 was
5.49 months versus 2.60 months for grades 0 to 1 (hazard
ratio: 0.59, 95% CI: 0.56–0.62, p  0.0001), respectively.
At the time of data cutoff, OS data were mature (25%
censored observations) for all but one subgroup (female
nonsmokers with nonsquamous tumors). Median OS ranged
from 5.03 months (in male nonsmokers with squamous tu-
mors) to 15.54 months (in female nonsmokers with nonsqua-
mous tumors).
Multivariate Analyses
Multivariate analyses were performed for PFS and OS
using the Cox regression model and for DCR using the
logistic regression model. For both the PFS and OS analyses,
data were available for 4729 patients, with 1851 patients
excluded because of missing values (Table 4). Of the patients
included in the PFS and OS analyses, 348 patients did not
experience progression, and 919 were alive at the last obser-
vation. Data for these patients were censored. The Cox
regression analysis showed that poor ECOG PS (2), smok-
ing, non-Asian ethnicity, squamous cell histology, stage IV
disease, and age 65 years were all predictive of early
disease progression. With the exception of age, the same
characteristics along with male gender were also predictive of
shorter OS. A multivariate logistic regression analysis for
DCR was also performed. Data were available for 3960
patients, with 2620 patients excluded because of missing
values. The optimal model for DCR showed that nonsmokers
with stage IIIB disease, ECOG PS 0/1, and Asian ethnicity
had significantly better prognosis in terms of DCR (Table 4).
Safety and Tolerability
Overall safety data were available for 6580 patients, of
whom 54% had one or more AE of any cause (excluding the
prespecified AEs defined in the protocol). Twelve percent of
patients had one or more erlotinib-related AE (excluding the
prespecified AEs defined in the protocol) (Table 5). Erlotinib-
related AEs (any grade; excluding the prespecified AEs
defined in the protocol) that were reported in more than 20
patients included mouth ulceration; paronychia; alanine ami-
notransferase increase; aspartate aminotransferase increase;
blood bilirubin increase; dysgeusia; and alopecia (Table 5).
FIGURE 1. Progression-free survival (A) and overall survival
(B) in patients receiving erlotinib (n  6580).
TABLE 2. Response Data in the Overall TRUST Population
(n  6580)
n (%)
Best response data available, n  5394
Complete response (CR) 45 (1)
Partial response (PR) 668 (12)
Objective response rate (ORR  CR  PR) 713 (13)
Stable disease (SD) 2992 (55)
Disease control rate (DCR  CR  PR  SD) 3705 (69)
Progressive disease (PD) 1483 (27)
Not evaluable (NE) 206 (4)
No best response data available, n  1186
Remaining patients in the study population for whom no
best response data were reported due to
Symptomatic deterioration 424 (36)
Death due to malignant disease 262 (22)
Patient refusal 179 (15)
Study drug-related AE 143 (12)
Death due to other reason 68 (6)
Other 49 (4)
Lost to follow-up 48 (4)
PD 10 (1)
Death due to toxicity 2 (1)
Not known 1 (1)
Total (all patients) 6580 (100)
TRUST, Tarceva Lung Cancer Survival Treatment; AE, adverse event.
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Of the seven patients (1%) who had erlotinib-related inter-
stitial lung disease (grades 1–2, n  2; grades 3–4, n  4;
grade 5, n 1), two deaths occurred. Only 4% of patients had
one or more erlotinib-related SAEs; diarrhea was the most
common single SAE, occurring in 1% of patients (Table 6).
Dose reduction of erlotinib was reported in 1096 (17%)
of the 6580 patients for whom data were available. In the
majority (95%) of these cases, the dose was reduced due to an
erlotinib-related AE, most commonly rash (65%) or diarrhea
(10%). In the overall safety population (n  6580), treatment
TABLE 3. Response and Survival in Selected Patient Subgroups, Defined on the Basis of Gender, Histology, and Smoking
Status
Group 1,
Male C/FS
with SCC
Group 2,
Male NS
with SCC
Group 3, Male
C/FS with
Nonsquamous
Tumors
Group 4, Male
NS with
Nonsquamous
Tumors
Group 5,
Female C/FS
with SCC
Group 6,
Female NS
with SCC
Group 7, Female
C/FS with
Nonsquamous
Tumors
Group 8, Female
NS with
Nonsquamous
Tumors
n (evaluable for response)a 944 78 1731 410 153 83 805 1183
CR, n (%) 0 (0) 1 (1) 5 (1) 9 (2) 0 1 (1) 3 (1) 26 (2)
PR, n (%) 42 (4) 8 (10) 144 (8) 78 (19) 8 (5) 13 (16) 75 (9) 300 (25)
SD, n (%) 616 (65) 37 (47) 954 (55) 224 (55) 87 (57) 38 (46) 417 (52) 614 (52)
PD, n (%) 246 (26) 28 (36) 559 (32) 85 (21) 56 (37) 26 (31) 274 (34) 208 (18)
NE, n (%) 40 (4) 4 (5) 69 (4) 14 (3) 2 (1) 5 (6) 36 (4) 35 (3)
ORR (%) 4 12 9 21 5 17 10 28
DCR (%) 70 59 64 76 62 63 61 79
n (evaluable for survival)b 1164 99 2216 488 193 94 994 1323
PFS (mo) 2.83 2.33 2.73 6.01 2.35 2.97 2.46 7.19
OS (mo) 5.98 5.03 5.95 13.21 5.19 9.40 7.26 15.54c
a Nine patients were not included in this analysis because of unknown smoking status (seven with response data available and two with response data “not done”).
b Nine patients were not included in this analysis because unknown smoking status.
c Data not mature.
C/FS, current or former smokers; SCC, squamous cell carcinoma; NS, nonsmokers; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease;
NE, not evaluable; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival.
TABLE 4. Multivariate Analyses for Progression-Free
Survival, Overall Survival, and Disease Control Rate
Factor (Cox Regression Model) Hazard Ratio 95% CI p
Factors for PFS, n  4729
Stage of disease (IV:IIIB) 1.23 1.14–1.32 0.0001
Histology (SCC:adeno/BAC) 1.19 1.11–1.28 0.0001
Smoking status (C/FS:NS) 1.58 1.47–1.69 0.0001
Ethnicity (non-Asian:Asian) 1.34 1.25–1.45 0.0001
Age (65 yr:65 yr) 1.08 1.01–1.14 0.0210
ECOG PS (2 or 3:0 or 1) 1.42 1.32–1.52 0.0001
Factors for OS, n  4729
ECOG PS (2 or 3:0 or 1) 2.01 1.86–2.16 0.0001
Smoking status (C/FS:NS) 1.53 1.40–1.66 0.0001
Ethnicity (non-Asian:Asian) 1.55 1.43–1.68 0.0001
Histology (SCC:adeno/BAC) 1.26 1.17–1.36 0.0001
Stage of disease (IV:IIIB) 1.22 1.13–1.33 0.0001
Gender (male:female) 1.11 1.03–1.20 0.0054
Factor (Logistic Regression Model) Odds Ratioa 95% CI p
Factors for DCR, n  3960
Ethnicity (non-Asian:Asian) 1.54 1.29–1.83 0.0001
Smoking status (C/FS:NS) 1.60 1.37–1.88 0.0001
Stage of disease (IV:IIIB) 1.29 1.09–1.53 0.0037
ECOG PS (2 or 3:0 or 1) 1.26 1.06–1.50 0.0086
a For response:no response.
PFS, progression-free survival; CI, confidence interval; SCC, squamous cell carci-
noma; BAC, bronchoalveolar carcinoma; C/FS, current or former smoker; NS, non-
smoker; ECOG PS, Eastern Cooperative Oncology Group performance status; OS,
overall survival; DCR, disease control rate.
TABLE 5. Erlotinib-Related Adverse Events (Any Grade)a
Reported in 20 Patients (n  6580)b
Events
Any Grade,
n (%)
Grades 3–4,
n (%)
Patients with any erlotinib-related AE 799 (12) 173 (3)
Blood and lymphatic system disorders 34 (1) 8 (1)
Eye disorders 71 (1) 5 (1)
Gastrointestinal disorders 108 (2) 16 (1)
Mouth ulceration 27 (1) 0
General disorders and administration site
conditions
56 (1) 20 (1)
Hepatobiliary disorders 32 (1) 11 (1)
Infections and infestations 174 (3) 21 (1)
Paronychia 137 (2) 5 (1)
Investigations 133 (2) 22 (1)
Alanine aminotransferase increased 23 (1) 3 (1)
Aspartate aminotransferase increased 22 (1) 2 (1)
Blood bilirubin increased 56 (1) 7 (1)
Metabolism and nutrition disorders 28 (1) 13 (1)
Musculoskeletal and connective tissue disorders 28 (1) 0
Nervous system disorders 93 (1) 8 (1)
Dysgeusia 31 (1) 0
Respiratory, thoracic, and mediastinal disorders 78 (1) 23 (1)
Skin and subcutaneous tissue disorders 189 (3) 17 (1)
Alopecia 102 (2) 0
a As defined by NCI-CTC criteria v3.0.
b Other than the most frequently occurring prespecified events.
AE, adverse event.
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was discontinued due to erlotinib-related AEs in 337 (5%) of
patients. The most common AEs leading to discontinuation were
rash (2%) and diarrhea (1%) (Table 7). Treatment-related SAEs
resulting in death occurred in 24 patients (1%), mainly be-
cause of respiratory, thoracic, and mediastinal disorders (n 10)
or infections and infestations (n  4).
In a separate analysis, the incidence and severity of
erlotinib-related rash was monitored among the 6580 patients
for whom safety data were available. These data were re-
corded separately on the case report forms. Erlotinib-related
rash was observed in 71% of patients. The majority (59%) of
cases were mild or moderate (grade 1/2) in severity, 12%
were grades 3 to 4, and 1% were classified as unknown
(grade of rash not reported).
DISCUSSION
The results of this international phase IV trial reflect
clinical experience with erlotinib in a wide range of more
than 6500 patients with advanced NSCLC. Differences in
local clinical practice and the broad eligibility criteria for this
study resulted in a large and heterogeneous patient population.
The conclusions from the study must be tempered by the
limitations of the open-label, nonplacebo controlled, single-arm
study design, one consequence of which is that no distinction
can be made between prognostic and predictive factors.
Our analyses confirm that erlotinib is an effective and
well-tolerated option for eligible patients with advanced
NSCLC. The PFS and OS in this study were 3.25 months and
7.9 months, respectively, and the DCR was 69%.
The criteria used for selecting the most appropriate
therapy for a patient are of particular interest to physicians.
Tumors with EGFR mutations have been shown to be highly
responsive to EGFR TKIs.8,11,18 Although patients whose
tumors have these mutations are likely to obtain a greater
magnitude of benefit from EGFR TKIs such as erlotinib, it is
important to note that the absence of these mutations does not
necessarily result in a lack of benefit with erlotinib therapy. In
the recent phase III SATURN study of erlotinib mainte-
nance therapy in patients obtaining clinical benefit from
standard first-line chemotherapy, erlotinib significantly
prolonged both PFS and OS in patients whose tumors did
not harbor EGFR mutations.19,20 As there was still some
uncertainty about the relevance of biomarkers to EGFR
TKIs when the TRUST study was designed, biomarker
investigations were only conducted as exploratory analy-
ses. Collection of tumor samples in this study was op-
tional, and, as a result, only a small number of TRUST
patients provided samples suitable for EGFR mutation
analyses (4.4%; Roche, data on file).
Current options for second-line treatment for patients
with advanced NSCLC include conventional chemotherapy
with docetaxel or pemetrexed, or targeted therapy with erlo-
tinib, or in some regions, gefitinib. Alternatively, some pa-
tients may elect to receive best supportive care or to partic-
ipate in a clinical trial. Clearly, patient characteristics such as
likelihood of response, in addition to the efficacy and safety
of the treatment, are among the primary considerations for
the selection of an appropriate therapy. This study, as well
as others, shows that erlotinib is generally well tolerated.
The class effect of skin toxicity may also be predictive of
response.
The results suggest that erlotinib can benefit a wide
range of patients, including those who have previously been
thought unlikely to benefit from treatment with EGFR TKIs.
Although response rates were particularly high for some
groups (nonsmokers with nonsquamous tumors) and lower
for others (current/former smokers with squamous cell carci-
noma), the DCR was at least 59% in all subgroups. The
median PFS in the eight predefined subgroups ranged from
2.33 to 7.19 months and was not substantially shorter than
that for the overall study population (3.25 months) in any of
the subgroups. These PFS data compare favorably with the
median PFS of 1.8 months reported for the placebo arm of the
BR.21 trial,1 indicating that all subgroups were likely to have
obtained some benefit from treatment with erlotinib. Simi-
larly, results from the phase III BR.21 study indicated that
erlotinib conferred a clinical benefit to most patient sub-
groups, although certain subgroups seem to have an enhanced
benefit from erlotinib therapy.1
There were no unexpected safety findings relating to
erlotinib in this study. As the prespecified expected treat-
ment-related AEs were not recorded (unless they resulted in
premature treatment withdrawal), it is not possible to com-
TABLE 7. Erlotinib-Related Adverse Events Leading to
Treatment Withdrawal in 1% Patients (n  6580)
Events
Any Grade,a
n (%)
Grades 3–4,
n (%)
Patients with any AE leading to withdrawal 337 (5) 213 (3)
Gastrointestinal disorders 121 (2) 74 (1)
Diarrhea 74 (1) 42 (1)
Skin and subcutaneous tissue disorders 133 (2) 78 (1)
Rash 113 (2) 67 (1)
a As defined by NCI-CTC criteria v3.0.
AE, adverse event.
TABLE 6. Erlotinib-Related Serious Adverse Events (Any
Grade)a Reported in 20 Patients (n  6580)
Events
Any Grade,
n (%)
Grades 3–4,
n (%)
Patients with any erlotinib-related SAE 274 (4) 209 (3)
Gastrointestinal disorders 121 (2) 89 (1)
Diarrhea 67 (1) 49 (1)
Nausea 24 (1) 11 (1)
General disorders and administration site
conditions
26 (1) 18 (1)
Infections and infestations 22 (1) 16 (1)
Metabolism and nutrition disorders 27 (1) 18 (1)
Respiratory, thoracic and mediastinal disorders 37 (1) 30 (1)
Skin and subcutaneous tissue disorders 40 (1) 31 (1)
Rash 31 (1) 26 (1)
a As defined by NCI-CTC criteria v3.0.
SAE, serious adverse event.
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ment on the frequency or severity of these events. Most AEs
were generally mild to moderate. The most common reasons
for erlotinib-related dose reductions or discontinuations were
rash and diarrhea; both of which are well-known class effects
of EGFR inhibitors.
Previous studies have shown a strong correlation be-
tween the degree of rash experienced by patients and survival
benefit, indicating that rash may be surrogate marker of
efficacy for erlotinib and other EGFR inhibitors.21 In our
study, comparison of PFS between patients who experienced
mild or no rash (grades 0–1) versus patients who experienced
a higher degree of rash (grades 2–4) showed that the PFS for
the high-grade rash group was at least twice as long in
duration compared with the low grade or no rash group.
These results are supportive of the proposed predictive rela-
tionship between rash and EGFR inhibitor benefit. Based on
the lack of prospective data, the difficulties to adequately
assess rash (because of dynamic changes in the rash during
treatment with erlotinib) and on our experiences with the
efficacy of erlotinib (even in patients without rash), it may not
be valid to use rash as a selection criterion for or against
treatment in clinical practice. Standard conventional assess-
ments (i.e., tumor imaging) should remain the measure of
efficacy.
The results of this global phase IV trial of erlotinib in
more than 6500 unselected patients with advanced NSCLC
confirm the suitability of erlotinib for use in patients who
are unsuitable for standard chemotherapy or have experi-
enced disease progression. These data confirm the favor-
able survival and safety profile of erlotinib in a global
patient population and across a broad range of patient
subgroups.
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